GxP Consulting Announces New Expansion Strategy into US and UK Markets

26-Aug-2009 - United Kingdom

GxP consulting, provider of compliance services to the pharmaceutical and biopharmaceutical industries, announced expansion plans in the US and UK markets. Led by Mark Stevens, managing director at GxP Consulting, the company has launched a strategy to expand services and support to customers in Europe and America in order to help businesses rise to the challenges currently being faced across the industry.

As part of this expansion, GxP Consulting announces a strategic new facility in Irvine, California, to support increased activity in North America. Secondly, expansion in the UK has led GxP Consulting to move its headquarters into a new larger purpose-built facility in Nottingham. With a dedicated team of 40 consultants in place, GxP Consulting is ideally placed to move forward with its new growth strategy and improved customer support in both regions.

Mark comments: "This is an exciting time for GxP Consulting. We recently marked our ten year anniversary, which is a significant milestone for any business and the next step for us is to push forward with our expansion strategy across both the USA and UK. In the last 12 months, our plans have seen us move to new headquarters in Nottingham, launch a brand new client-centric website and extend our range of services. 2009 is a crucial year for the company as we look to build on our success over the last 12 months, extend our customer support throughout Europe and North America and continue to grow our portfolio of services."

Other news from the department business & finance

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?

Last viewed contents

BioGaia signs distribution and license agreements with partner in Japan

Mechanism for DNA Invasion of Adenoviral Covid-19 Vaccines Discovered - Premature release of DNA activates anti-viral alarm systems

Mechanism for DNA Invasion of Adenoviral Covid-19 Vaccines Discovered - Premature release of DNA activates anti-viral alarm systems

Herceptin now approved in the EU for patients with HER2-positive advanced stomach cancer - First targeted biological therapy to show survival benefit in stomach cancer

Cancer Treatment with Built-in Light - Deep photodynamic therapy: photosensitizer irradiates itself

Cancer Treatment with Built-in Light - Deep photodynamic therapy: photosensitizer irradiates itself

Silence Therapeutics Forms Scientific Advisory Board

Proteins roll the dice to determine bee sex - “We have been able to solve a genetic mystery that has existed for more than 100 years"

Proteins roll the dice to determine bee sex - “We have been able to solve a genetic mystery that has existed for more than 100 years"

Baxalta gains Health Canada approval for OBIZUR - Treatment for patients with acquired hemophilia A

InteRNA Technologies and Dana-Farber Cancer Institute to collaborate on the role of microRNAs in cancer pathways

Domainex Collaborates with Sigma-Aldrich to Advance the Study of Epigenetic Proteins Involved in Cancer and Stem Cell Biology

Stanford researchers explore link between human birth defect syndrome, cancer metastasis

Galapagos successfully completes Phase I clinical trials for rheumatoid arthritis candidate drug GLPG0259 - Phase II efficacy study in rheumatoid arthritis patients planned to start later this year

UF oncologists fight leukemia with two-pronged therapy, clinical trials to start within months